Neurogene Initiates PPQ Campaign, Extends Cash Runway to 2029 After Q2 Results
NGNE has more than doubled off its 52-week low of $15.93.
Summary
Neurogene reported Q2 2026 financials and announced the initiation of its PPQ campaign in July, a critical step toward a planned BLA submission for NGN-401 in Rett syndrome. The company expects to complete PPQ runs by year-end 2026, with topline Embolden registrational data now guided for the second half of 2027. Cash and equivalents stood at $225.4 million as of June 30, with pro forma cash of approximately $360.2 million after the July offering, extending the runway into Q1 2029. R&D expenses rose to $25.5 million from $19.4 million a year ago, driven by NGN-401 clinical and CMC activities. The updated safety profile across 35 treated participants remains clean, supporting the registrational path. This follows the positive long-term Phase 1/2 data in June and the $135 million equity raise in July, reinforcing the company's commercial-readiness trajectory.
At the time of this announcement, NGNE was trading at $36.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $728.3M. The 52-week trading range was $15.93 to $43.66. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.